STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests

STAT PlusPharmalot Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests The projected savings may be reduced by as much as 80% Manage alerts for this article Email this article Share this article By Ed SilvermanSept. 13, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

The projected savings from a highly touted Trump administration plan to lower Medicare drug costs may be drastically reduced — by as much as 80% — thanks to secretive deals cut with more than two dozen pharmaceutical companies, according to a new analysis. At issue is an approach known as “most-favored nation” pricing, which would tie the prices paid by Medicare to what 19 other wealthy nations pay for the same medicines. The White House has maintained the effort would save Medicare $26 billion over several years and help mitigate the long-standing problem of increasingly unaffordable prescription drugs.Advertisement To make this happen, the administration is creating two pilot programs — GLOBE for Medicare Part B and GUARD for Medicare Part D — that will require drug companies to pay additional rebates if their prices exceed the lowest international price found in those 19 countries.

More specific details about the rules are due shortly. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug pricing, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot September 11, 2026 STAT Plus: Pharma wins a battle over the cost of wastewater treatment in Europe Pharmalot September 11, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Advertisement Pharmalot September 11, 2026 STAT Plus: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more Pharmalot September 10, 2026 STAT Plus: The gifts from pharma companies that keep on giving Pharmalot September 10, 2026 STAT Plus: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more Subscriber Picks